Drugs / RNDO-564
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07218003 | Nov 2025 → Feb 2029 expected | cervical cancer, esophageal squamous cell carcinoma, gastric cancer, gastroesophageal junction adenocarcinoma +4 | Rondo Therapeutics | Enrolling by invitation | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RNDO-564 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07218003 ↗ |